Literature DB >> 10667602

A specific sequence of the noncollagenous domain of the alpha3(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells.

S Pasco1, J Han, P Gillery, G Bellon, F X Maquart, J P Borel, N A Kefalides, J C Monboisse.   

Abstract

The invasive properties of melanoma cells correlate with the expression of matrix metalloproteinases (MMPs) and their physiological modulators (tissue inhibitors of metalloproteinase and membrane-type MMPs) and with that of the alphaVbeta3 integrin. We investigated the effect of anterior lens capsule type IV collagen and of the alpha3(IV) collagen chain on the invasive properties of various tumor cell lines (HT-144 melanoma cells, HT-1080 fibrosarcoma cells). We demonstrated that anterior lens capsule type IV collagen or specifically the synthetic peptide alpha3(IV) 185-203 inhibited both the migration of melanoma or fibrosarcoma cells as well as the activation of membrane-bound MMP-2 by decreasing the expressions of MT1-MMP and the beta3 integrin subunit.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667602

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

2.  Down-Regulation of MT1-MMP expression by the alpha3 chain of type IV collagen inhibits bronchial tumor cell line invasion.

Authors:  C Martinella-Catusse; M Polette; A Noel; C Gilles; P Dehan; C Munaut; A Colige; L Volders; J C Monboisse; J M Foidart; P Birembaut
Journal:  Lab Invest       Date:  2001-02       Impact factor: 5.662

3.  Melanoma cell migration to type IV collagen requires activation of NF-kappaB.

Authors:  Louis Hodgson; Andrew J Henderson; Cheng Dong
Journal:  Oncogene       Date:  2003-01-09       Impact factor: 9.867

4.  Tetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine.

Authors:  Sylvie Brassart-Pasco; Karine Sénéchal; Jessica Thevenard; Laurent Ramont; Jérome Devy; Ludivine Di Stefano; Aurélie Dupont-Deshorgue; Stéphane Brézillon; Jezabel Feru; Jean-François Jazeron; Marie-Danièle Diebold; Sylvie Ricard-Blum; François-Xavier Maquart; Jean Claude Monboisse
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

5.  Collagen type IV at the fetal-maternal interface.

Authors:  C M Oefner; A Sharkey; L Gardner; H Critchley; M Oyen; A Moffett
Journal:  Placenta       Date:  2014-11-01       Impact factor: 3.481

6.  Type IV collagen α1-chain noncollagenous domain blocks MMP-2 activation both in-vitro and in-vivo.

Authors:  Yakkanti Akul Sudhakar; Raj Kumar Verma; Smita C Pawar
Journal:  Sci Rep       Date:  2014-03-26       Impact factor: 4.379

Review 7.  Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression.

Authors:  Stephan Niland; Andrea Ximena Riscanevo; Johannes Andreas Eble
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

8.  Lumican - derived peptides inhibit melanoma cell growth and migration.

Authors:  Katarzyna Pietraszek; Stéphane Brézillon; Corinne Perreau; Maria Malicka-Błaszkiewicz; François-Xavier Maquart; Yanusz Wegrowski
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

Review 9.  Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression.

Authors:  Akulapalli Sudhakar; Chandra S Boosani
Journal:  Pharm Res       Date:  2008-06-13       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.